| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| Other Sizes |
|
Purity: ≥98%
Bethanechol Chloride (also known as Carbamyl-β-methylcholine chloride) is a parasympathomimetic choline carbamate and an analog of acetylcholine with a long duration of action due to improved metabolic stability. Unlike acetylcholine, bethanechol is not hydrolyzed by cholinesterase. It has been used to treat certain bladder problems such as the inability to urinate or empty the bladder completely due to certain causes. It acts as a selective muscarinic receptor agonist without any effect on nicotinic receptors. Bethanechol alleviates dry mouth and is sometimes given orally or subcutaneously to treat urinary retention resulting from general anesthetic, diabetic neuropathy of the bladder, or a side effect of antidepressants; or to treat gastrointestinal lack of muscular tone.
| ln Vitro |
Ileal pacemaker potential is considerably decreased by carbachol chloride (0.3-300 μM) [2].
|
|---|---|
| ln Vivo |
In rats, dose-dependent increases in urine production and alcohol consumption are induced by methacholine (2–12 mg/kg) administered intraperitoneally [4].
|
| Animal Protocol |
Animal/Disease Models: Blue Spruce Farm (SD (SD (Sprague-Dawley))) female rats (280-330 g) [4]
Doses: 2 mg/kg, 4 mg/kg, 8 mg/kg, 12 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: Water intake increased in a dose-dependent manner during the first hour up to the highest dose administered (12 mg/kg). |
| References | |
| Additional Infomation |
Bethanechol chloride is the chloride salt of bethanechol. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention. It has a role as a muscarinic agonist. It is a carbamate ester, a quaternary ammonium salt and a chloride salt. It contains a bethanechol.
Bethanechol Chloride is a synthetic quaternary ammonium base derivative, parasympathomimetic Bethanechol is a slowly hydrolyzed muscarinic agonist with no nicotinic effects. Generally used to increase smooth muscle tone, Bethanechol is used to treat reflux esophagitis and to initiate urination after surgery, in urinary infections, or for enlarged prostate. It may cause hypotension, cardiac rate changes, and bronchial spasms. (NCI04) A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM. See also: Bethanechol (has active moiety). |
| Molecular Formula |
C7H17N2O2.CL
|
|
|---|---|---|
| Molecular Weight |
196.68
|
|
| Exact Mass |
196.097
|
|
| CAS # |
590-63-6
|
|
| Related CAS # |
Bethanechol;674-38-4;Bethanechol-d6 chloride
|
|
| PubChem CID |
11548
|
|
| Appearance |
White to off-white solid powder
|
|
| Melting Point |
187-190ºC
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
12
|
|
| Complexity |
140
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
XXRMYXBSBOVVBH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C7H16N2O2.ClH/c1-6(11-7(8)10)5-9(2,3)4;/h6H,5H2,1-4H3,(H-,8,10);1H
|
|
| Chemical Name |
2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium chloride
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (508.44 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0844 mL | 25.4220 mL | 50.8440 mL | |
| 5 mM | 1.0169 mL | 5.0844 mL | 10.1688 mL | |
| 10 mM | 0.5084 mL | 2.5422 mL | 5.0844 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05299008 | Recruiting | Drug: Bethanechol | Tracheobronchomalacia | Arkansas Children's Hospital Research Institute | August 11, 2022 | |
| NCT03572283 | Recruiting | Drug: Bethanechol | Pancreas Cancer | Columbia University | April 8, 2018 | Early Phase 1 |
| NCT05241249 | Recruiting | Drug: Bethanechol Drug: Gemcitabine Drug: nab-paclitaxel |
Pancreas Cancer | Susan E. Bates | February 1, 2022 | Phase 2 |
| NCT01031043 | Completed Has Results | Drug: Bethanechol | Esophageal Dysmotility | Augusta University | November 2009 | Phase 1 |
| NCT02058537 | Terminated Has Results | Drug: Bethanechol | Eosinophilic Esophagitis (EoE) | University of Iowa | February 2014 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA